tag:blogger.com,1999:blog-36768584.post3411050364384778746..comments2024-03-03T18:49:34.382-05:00Comments on Omics! Omics!: Roche Expands Sequencing Nanopore Presence by Acquiring Stratos GenomicsKeith Robisonhttp://www.blogger.com/profile/04765318239070312590noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-36768584.post-3393372648485442462020-09-07T00:29:38.327-04:002020-09-07T00:29:38.327-04:00They have motion control and will be porting over ...They have motion control and will be porting over to the Genia platform Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36768584.post-17184364092187347882020-09-03T03:18:08.842-04:002020-09-03T03:18:08.842-04:00I don't get it, why don't Roche just make ...I don't get it, why don't Roche just make an offer for ONT? They'd get them at 2-3 billion maybe (not much money for them and they get an already working diagnostic with huge potential)? <br />It seems exceedingly doubtful Roche will change habit of a lifetime and develop anything.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36768584.post-9195853634580835192020-06-01T07:12:06.424-04:002020-06-01T07:12:06.424-04:00The acquisition price seems to have been below rep...The acquisition price seems to have been below reporting requirements (unless I've missed something). So I suspect it was acquired at a relatively low price.<br /><br />Roche had previously invested in them, which also may have locked out some buyers?<br /><br />I don't think I saw anything in the patents about motion control. Unless the expansion is from 1bp to kilobases+, I would imagine they would still need some kind of motion control to get a readout (or maybe bulkier labels?).<br /><br />From memory their patents refer to alpha-hemolysin, which probably isn't the best pore to be using.<br /><br />So, I had lots of open questions. They are not the first company to try and get an "expandomer" type approach working. So I suspect it's problematic. And if it can be made to work, it might be difficult to produce something competitive.<br /><br />Will be interesting to follow patents and publications to see how things develop.Nava Whitefordhttp://41j.comnoreply@blogger.com